SHANGHAI, China, Oct. 23 /Xinhua-PRNewswire/ -¡ª WuXi PharmaTech (Cayman) Inc. (“WuXi PharmaTech” or “the Company”), the leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release unaudited financial results for the third quarter ended September 30, 2007 after the US market closes on Monday, November 12, 2007.
The earnings release will be available on the investor relations page of its website at http://www.wuxipharmatech.com.
Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (Eastern) / 5:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong) on Tuesday, November 13, 2007 to discuss its 2007 third quarter financial results and recent business activity. The conference call may be accessed by calling:
A telephone replay will be available shortly after the call until December 12, 2007 at (US) +1-888-203-1112/ (UK) +0-808-101-1153 / (HK) +800-901-108. Passcode: 7947278.
A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech’s website at http://www.wuxipharmatech.com.
About WuXi PharmaTech
Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech’s services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, pharmaceutical development and process development services, and manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use. In 2006, WuXi PharmaTech provided services to 70 pharmaceutical and biotechnology customers, including nine of the top ten pharmaceutical companies in the world, as measured by 2006 total revenues. For more information, please visit: http://www.wuxipharmatech.com.
ir@pharmatechs.comPharmatechs@taylor-rafferty.comPharmatechs@taylor-rafferty.comPharmatechs@taylor-rafferty.com
CONTACT: Investor Contact: Dr. Hai MiVice, President, Corporate
Communications of WuXi PharmaTech Co., Ltd at +86-21-5046-3726 or
ir@pharmatechs.com; Investor Relations, US: Mahmoud Siddig, Director of
Taylor Rafferty at +1-212-889-4350 or Pharmatechs@taylor-rafferty.com;
Investor Relations, HK: Ruby Yim, Managing Director of Taylor Rafferty at
+852-3196-3712 or Pharmatechs@taylor-rafferty.com; Media Contact: John
Dooley of Taylor Rafferty at +1-212-889-4350 or
Pharmatechs@taylor-rafferty.com
Web site: http://www.wuxipharmatech.com/
